The WIA-BIO-020 standard establishes comprehensive protocols for Stem cells, tissue regeneration, ensuring interoperability, reproducibility, and regulatory compliance.
| Feature | Description |
|---|---|
| Data Standards | Standardized formats and protocols |
| Quality Control | Validation metrics and acceptance criteria |
| Regulatory Compliance | FDA/EMA guidelines |
Broadly Benefiting Humanity
The WIA-BIO-020 standard follows the canonical four-Phase WIA Standards architecture. Phase 1 fixes the data-format envelopes for regenerative-medicine cell preparations, growth factors, scaffolds, clinical applications, and quality records; Phase 2 surfaces the API contract through HTTPS; Phase 3 codifies the protocol exchanges that cross trust boundaries; Phase 4 integrates the standard with the broader ecosystem (regulatory cross-walks, partner adapters, and reference deployments).
| Phase | Scope | Document |
|---|---|---|
| Phase 1 | Data Format | PHASE-1-DATA-FORMAT.md |
| Phase 2 | API Interface | PHASE-2-API.md |
| Phase 3 | Protocol | PHASE-3-PROTOCOL.md |
| Phase 4 | Integration | PHASE-4-INTEGRATION.md |
WIA-BIO-020 adopts the WIA Standards three-Tier conformance model: Tier 1 self-declared (internal use, pilot deployments), Tier 2 third-party assessed (external partners, B2B integrations), Tier 3 accredited (public-facing or regulated deployments per ISO/IEC 17065:2012). Implementations declare their tier in the OpenAPI info.x-wia-tier extension and on any public certification page. Tier downgrade events are reported to the WIA registry within 30 days. The conformance test suite covers every Phase 1 envelope, every Phase 2 endpoint, and every Phase 3 protocol exchange, and is published under the WIA-Official GitHub organisation.